Cancer Screening among Rural People Who Use Drugs: Colliding Risks and Barriers

Wiley D. Jenkins 1,⁎, Jennifer Rose 2, Yamile Molina 3, Minjee Lee 1,4⁎, Rebecca Bolinski 5, Georgia Luckey 2⁎ and Brent Van Ham 6

Abstract: Rural cancer disparities are associated with lesser healthcare access and screening adherence. The opioid epidemic may increase disparities as people who use drugs (PWUD) frequently experience healthcare-associated stigmatizing experiences which discourage seeking routine care. Rural PWUD were recruited to complete surveys and interviews exploring cancer (cervical, breast, colorectal, lung) risk, screening history, and healthcare experiences. From July 2020–July 2021 we collected 37 surveys and 8 interviews. Participants were 24.3% male, 86.5% White race, and had a mean age of 44.8 years. Females were less likely to report seeing a primary care provider on a regular basis, and more likely to report stigmatizing healthcare experiences. A majority of females reporting receiving recommendations and screens for cervical and breast cancer, but only a minority were adherent. Similarly, only a minority of males and females reported receiving screening tests for colorectal and lung cancer. Screening rates for all cancers were substantially below those for the US generally and rural areas specifically. Interviews confirmed stigmatizing healthcare experiences and suggested screening barriers and possible solutions. The opioid epidemic involves millions of individuals and is disproportionately experienced in rural communities. To avoid exacerbating existing rural cancer disparities, methods to engage PWUD in cancer screening need to be developed.

Keywords: rural cancer disparities; rural cancer screening; cancer screening and adherence

1. Introduction

Approximately 19% of the US population (~60 million people) resides in rural areas, and faces significant disparities regarding cancer screening, incidence, and mortality [1]. Recent studies report that rural individuals experience increased incidence rates, and later stages of diagnosis, of cancers of the colon and rectum (CRC), breast (BC), and cervix (CC) [2–4]. During 2006–2015, the annual age-adjusted death rates for all cancer sites combined decreased at a slower pace in nonmetropolitan areas (~1.0% per year) than in metropolitan areas (~1.6% per year), increasing the differences in these rates [5]. These cancers are also associated with modifiable risk factors and behaviors (e.g., tobacco and alcohol use, human papillomavirus (HPV) infection, obesity, screening utilization), many of which more frequently occur in rural communities [3,6–8]. Cumulatively, rural disparities in cancer incidence and mortality are significant and increasing.

Compounding modifiable risks, rural residents also face a multitude of barriers to healthcare access, including cultural norms, financial constraints, limited services, and
insufficient public transportation [9–17]. Physician shortages and Health Profession Shortage Areas are more common, with only 12% of primary care physicians working in rural areas (and 8% of specialty physicians) [18]. Further, while the overall number of physicians in the US grew by 16,000 during 2013–2015, the rural total dropped by 1400, and 26% of rural residents report not getting needed healthcare in the past few years [18,19]. Physical access is also decreasing, and since 2010 nearly 7% (120+) of rural hospitals have closed and another 25% face closure (this report before the COVID-19 pandemic and associated financial impact on healthcare organizations) [20]. These shortages likely contribute to findings that rural residents are less likely to report recommendations for, or receipt of, preventive services and cancer screening [11,21]. In spite of increased cancer risk and incidence in rural areas, access to healthcare is increasingly difficult to obtain.

Another contemporary epidemic is that associated with opioid and other illicit drug use. The extent of this epidemic is indicated in various reports showing that: 23.9% of those aged 18–25 reported using illicit drugs during the past month (2018); ~23 million US residents experienced substance use disorder (SUD) at some point (2015); and 2.6% of the US population aged 13 years or older had ever injected drugs and clinical studies indicate this may be increasing [22–25]. Ultimately, much of drug use and related adverse health outcomes are disproportionately experienced in rural areas, which face increased rates of use of opioids, alcohol, cigarettes, smokeless tobacco, and methamphetamine [26,27]. Further, clinicians often have high levels of stigma and negative attitudes towards patients with substance use disorders, which lessen both treatment outcomes and patient empowerment [28,29]. Subsequently reflected in the patient experience (via healthcare interactions and other situations), internalized stigma has been found to have negative impacts on individual mental health and health seeking behavior [30–40]. The US drug use epidemic is impacting millions of residents, disproportionately so in rural areas with already-diminished healthcare access. Further, widely prevalent healthcare-associated stigma towards substance use, and the internalization of such stigma, serves as both a barrier to proper treatment receipt and even treatment seeking among people who use drugs (PWUD). Members of our team have documented high levels of PWUD stigma among rural communities, which may be exacerbated during the COVID-19 pandemic [41,42].

We argue that rural PWUD face at least equal cancer risk as other rural individuals but may also be less likely to receive recommended screenings due in part to stigmatizing healthcare experiences. The purpose of this mixed-methods study was to explore how demographics, stigmatizing healthcare experiences, and cancer experience are associated with cancer screening recommendations, screening receipt, and current screening adherence (i.e., up-to-date) among rural people who use drugs.

2. Materials and Methods

2.1. Recruitment

For this initial exploration of cancer risk and screening knowledge we utilized a mixed-methods approach whereby a convenience sample of individuals was recruited to complete a survey, and a subset of these same participants subsequently invited to participate in an interview. Participants were recruited from the existing Ending Transmission of HIV, HCV, and STDs and Overdose in Rural Communities of People who Inject Drugs (ETHIC) clinical trial (NCT04427202) from July 2020 through July 2021. ETHIC eligibility includes: age ≥ 15 years; injection (any drug) OR non-injection opioid use to get high within the past 30 days; English-speaking; and ability to provide informed consent. Additional criteria for inclusion in this study included being eligible for at least one cancer screen due to age and/or smoking history. The age ranges were determined according to the United States Preventive Services Task Force screening recommendations, which are: females only aged 21–65 years (cervical) and 50–74 (breast); and males and females aged 50–75 years (colorectal) and 50–80 years plus 20 pack-year smoking history (lung) [43–46].
2.2. Surveys
Survey sections explored participant demographics; cancer screening knowledge and ever receipt of clinician recommendation for screening; screening history and barriers; and personal and family cancer history. We also asked four questions specifically related to healthcare access and use in relation to their drug use. Termed stigmatizing healthcare experiences (SHE), they were as follows: SHE-1: Have you ever avoided health care because of your drug use?; SHE-2: Have you ever had a healthcare worker refuse to treat you or denied you access to medical treatment or care because of your drug use?; SHE-3: Do you feel ‘accepted’ and ‘non-judged’ during office visits?; and SHE-4: Have you ever had bad experiences with primary care such that you considered not going anymore?

2.3. Interviews
Interviews were designed to elicit more contextual aspects of cancer risk and screening access and utilization. Interviews lasted about fifteen minutes and were audio-recorded by placing a digital recorder next to the telephone. Interviews were conducted (and previous surveys as well) by study staff experienced with both as part of the larger ETHIC clinical trial from which these participants were recruited. The interview guide and survey instrument are available online at Supplementary Material File S1.

2.4. Data Analysis
Survey data were subjected to descriptive, t-test, and cross tabulation analysis in SPSS. Due to the limited number of surveys and wide variation in some data, more complex analyses such as regression and modeling were not justified. Interview recordings were supplemented with detailed written notes. These field notes were subsequently verified and expanded by listening back to interview recordings, coded, and subjected to preliminary thematic analysis.

Due to COVID-19 social distancing requirements, we were unable to perform in-person recruitment or meet individuals during normal service delivery. Thus, recruitment for the survey was substantially hindered, and consisted entirely of calling and texting current ETHIC participants. We then selected a convenience sample of survey participants to invite for an interview, with selection seeking to maximize diversity in gender, race, and drug of choice. All surveys and interviews were conducted by phone and data entered into REDCap. Participants were reimbursed for their time ($20 for the survey, and an additional $20 if selected for interview). This study was approved by the University of Chicago Institutional Review Board.

3. Results
From 27 July 2020 to 13 July 2021 we invited 37 current ETHIC enrollees to participate in the survey, and all (100%) agreed. Participants were 24.3% male, 86.5% White race, and had a mean age of 44.8 years (range of 23–66; Table 1). Due to gender-based differences in cancer screening eligibility, male participants were aged 51–66 years while females were aged 23–62 years. Distribution of race, marital status, and education level did not significantly differ between males and females, though age was significantly different ($p < 0.001; as expected). All but one participant reported an income <$25,000. Regarding behaviors, the majority reported: no past month alcohol consumption; moderate physical activity 4.7 days/week; and past month participation in physical activity (no significant differences). A large majority also reported past and/or current smoking, with a significant difference in average pack-years ($p = 0.016; the difference is nonsignificant if comparison limited to those aged 50+ years). Regarding healthcare engagement and experiences, differences in engagement in routine care, care avoidance due to drug use, and feelings of acceptance in the healthcare environment were observed but not statistically significant. Finally, there are no significant differences in reported personal cancer diagnosis, or diagnosis among close family members.
Table 1. Participant demographics, alcohol and tobacco use, and experiences with healthcare and cancer (n = 37).

| Variable | Male (n = 9) | Female (n = 28) | p |
|----------|-------------|-----------------|---|
| Age (mean; range)** | 57.1; 51–66 | 40.8; 23–62 | <0.001 |
| Race (% White race) | 88.9% | 85.7% | 0.648 |
| Marital status** | | | 0.346 |
| Never married | 0 | 21.4 | |
| Married | 22.2 | 17.9 | |
| Separated/divorced/widowed | 44.4 | 46.4 | |
| Cohabitating | 33.3 | 14.3 | |
| Education level** | | | 0.085 |
| Elementary | 11.1 | 0 | |
| HS | 33.3 | 64.3 | |
| College | 55.6 | 35.7 | |
| During the past 30 days, how many days per week did you have at least one drink of any alcoholic beverage? (% none) | 66.7 | 64.3 | 0.614 |
| In a typical week, how many days do you do any physical activity or exercise of at least moderate intensity? (mean) | 4.7 | 4.7 | 0.965 |
| During the past month, did you participate in any physical activities or exercises such as running, yoga, golf, gardening, or walking for exercise? (% yes) | 77.8 | 85.7 | 0.457 |
| Do you now, or have you in the past, smoked cigarettes? (% yes) | 88.9 | 96.4 | 0.432 |
| Average pack years** | 33.6 | 22.9 | 0.016 § |
| How long have you been going to this provider? | | | 0.623 |
| Less than 6 months | 0.0 | 9.1 | |
| At least 6 months but less than 1 year | 16.7 | 0.0 | |
| At least 1 year but less than 3 years | 16.7 | 27.3 | |
| At least 3 years but less than 5 years | 33.3 | 27.3 | |
| 5 years or more | 33.3 | 36.4 | |
| SHE-1: Have you ever avoided health care because of your drug use? (% yes) | 44.4 | 75.0 | 0.100 |
| SHE-2: Have you ever had a healthcare worker refuse to treat you or denied you access to medical treatment or care because of your drug use? (% yes) | 22.2 | 35.7 | 0.376 |
| SHE-3: Do you feel ‘accepted’ and ‘non-judged’ during office visits? | No, they treat me differently | 22.2 | 46.4 | 0.208 |
| Yes, and they know about the drug use | 44.4 | 42.9 | |
| Yes, but they don’t know about the drug use | 33.3 | 10.7 | |
| SHE-4: Have you ever had bad experiences with primary care such that you considered not going anymore? (% yes) | 44.4 | 57.1 | 0.388 |
| Cancer experiences | | | |
| Have you ever been told by a health care provider that you have a cancer? (% yes) | 11.1 | 17.9 | 0.543 |
| Has a parent, sibling, or child related to you by blood ever been diagnosed with cancer? (Include only siblings with same biological mother and father). (% yes) | 66.7 | 67.9 | 0.829 |

** items are expected to differ due to different age ranges of screening eligibility for males and females. § This difference is insignificant if only assessed among those aged 50+ years.

We next explored receipt of cancer screening recommendations; if the individual ever received specific screenings; and if the individual was past due for screening due to age, risk, and length of time since last reported screen (Table 2).
| Gender | Cancer Site (Eligibility; # Eligible) | Recommendation? (n; %) | Ever Receipt? n (%) | Current Screening Adherence (%) | Participants | IL | US (All) | US (Rural vs. Urban) |
|--------|-----------------------------------|------------------------|---------------------|--------------------------------|--------------|----|----------|----------------------|
|        |                                   |                        |                     |                                |              |    |          |                      |
|        |                                   | Cervical cytology = 24 (85.7) | 23 (82.1)           |                               | 46.4         | 79.4 [47] | 80.2 [48] | 81.3 [47] | 77.7 vs. 84.4 [49] |
|        |                                   | HPV DNA = 6 (21.4)     | 5 (17.9)            |                               |              |    |          |                      |
| Females| Cervical (age 21–65; n = 28)      |                        |                     |                                |              |    |          |                      |
|        |                                   | Mammography = 6 (88.7) | 5 (71.4)            |                               | 42.9         | 78.1 [47] | 78.3 [48] | 71.7 [47] | 81 vs. 81 [50]    |
|        |                                   | MRI = 1 (14.3)         | 0 (0)               |                               |              |    |          |                      |
|        |                                   | Colonoscopy = 3 (42.9) | 3 (42.9)            |                               | 14.3         | 75.9 [51] | 73.5 [52] | 63.4 [47] | 78 vs. 82 [50]    |
|        |                                   | CT = 0 (0)             | 0 (0)               |                               |              |    |          |                      |
|        |                                   | Sigmoidoscopy = 0 (0)  | 0 (0)               |                               |              |    |          |                      |
|        |                                   | Stool = 1 (14.3)       | 0 (0)               |                               |              |    |          |                      |
|        |                                   | LDCT = 1 (16.7)        | 1 (16.7)            |                               | 0            | 6.3 [53] § | 5.7 [54] § | 17.5 [53] § | 16.3 vs. 17.7 [53] § |
| Males  |                                   |                        |                     |                                |              |    |          |                      |
|        |                                   | Colonoscopy = 5 (55.6) | 3 (33.3)            |                               | 33.3         | 62.0 [51] | 71.2 [52] | 61.9 [47] | 65.5 vs. 68.2 [51] § |
|        |                                   | CT = 2 (22.2)          | 1 (11.1)            |                               |              |    |          |                      |
|        |                                   | Sigmoidoscopy = 0 (0)  | 0 (0)               |                               |              |    |          |                      |
|        |                                   | Stool = 4 (44.4)       | 2 (22.2)            |                               |              |    |          |                      |
|        |                                   | LDCT = 0 (0)           | 0 (0)               |                               | 0            | 6.3 [53] § | 5.7 [54] § | 17.5 [53] § | 16.3 vs. 17.7 [53] § |

§ data are for combined sexes.
3.1. Cervical Cancer Screening

All 28 female participants were eligible. The majority reported receiving a cervical cytology recommendation and also receiving the test. For the high risk HPV test, only a minority reported receiving either a recommendation or the test. A majority (53.6%) of females were past due for a cervical cancer screen.

3.2. Breast Cancer Screening

Seven of the female participants were eligible. The majority reported receiving a mammography recommendation and also receiving the test. Only one reported a recommendation for the breast MRI exam, and none reported receipt. A majority (57.1%) of females were past due for a breast cancer screen.

3.3. Colorectal Cancer Screening

Seven of the female and all the male participants (combined \( n = 16 \)) were eligible. Approximately half of females and males received a recommendation for colonoscopy, and a minority of individuals reported recommendations for CT colonoscopy, sigmoidoscopy, and stool test. Less than half of individuals (6) reported ever receipt of a colonoscopy, small minorities reported receipt of CT colonoscopy (1) or stool (2) and none for sigmoidoscopy. A majority of both females and males (combined 80.0%) were past due for a colorectal cancer screen.

3.4. Lung Cancer Screening

Six of the female and 8 of the male participants (combined \( n = 14 \)) were eligible. Only 1 female (and no males) had received a recommendation and reported screening receipt. All 16 (100%) were past due for a lung cancer screen.

From the survey participants we successfully recruited 8 individuals to complete interviews. Interviewees were 50% male, 87.5% White race, and reported a diversity of drug of choice (cocaine, opioids, methamphetamine; Table 3). Survey findings are consistent with data from participant interviews which illustrate a lack of familiarity with cancer screening guidelines, some ambivalence about the receipt of cancer screening recommendations, and difficulties with engaging in routine care.

### Table 3. Selected interviewee characteristics.

| Pseudonym | Age | Sex  | Race  | Drug of Choice          |
|-----------|-----|------|-------|-------------------------|
| Billy     | 66  | Male | White | methamphetamine         |
| Calvin    | 59  | Male | White | opioids                 |
| Carol     | 62  | Female | White | opioids                 |
| Frank     | 58  | Male | Black | cocaine                 |
| Harry     | 61  | Male | White | cocaine                 |
| Julia     | 50  | Female | White | methamphetamine         |
| Laura     | 50  | Female | White | methamphetamine         |
| Sheryl    | 42  | Female | White | opioids                 |

Laura, a 50-year-old woman who injects methamphetamine, related her lack of knowledge around screening guidelines and being overdue for recommended screenings to her drug use saying, “... in this area, if you are an addict, they—the percentage of people that actually go to the doctor is really low. We end up going to the community health clinics here, and they don’t, uh, tell you about the availability of these [cancer screenings] unless you already know them.” Laura went on to say, “... the stigma here at family practice, at [local hospital], is if you use methamphetamine, you are not gonna get treatment that is of quality, really...”
Similarly, Billy, a 66-year-old man who endorses methamphetamine injection reported being “shut out” of the primary care office in his town due to his drug use history. When asked about receiving recommended cancer screenings, Frank, a 58-year-old Black man who uses cocaine and opioids, stated, “A lot of times, it’s kinda hard because, I had to go sixty-some miles to get that help, you know what I’m sayin’?”

Taken together, interview participants questioned the quality of care they received due to their drug use, and some reported traveling hours, even out of state, to access healthcare and receive cancer screenings at hospitals where they felt they were treated more fairly. Lastly, survey data were examined for associations between the two cancer history experiences (i.e., participant and family member past cancer diagnosis), the four stigmatizing healthcare experiences questions (SHE-1-4), and current screening status. While only one association was statistically significant (Table 4), the following points were noted.

Responses for SHE-1, SHE-2, and the cancer experiences are not consistent in indicating they may be a barrier or facilitation to screening. Feeling accepted by their provider who knows about their drug use (SHE-3) is consistently more frequently reported by those current with CC, BC and CRC and less so by those past due. Bad experiences in healthcare (SHE-4) are more frequently reported among those past due for CC, BC, and CRC.

Females who reported a family member with a cancer diagnosis were more likely to be up-to-date with cervical cancer screening, but no other cancer diagnosis (personal or family) was associated with any other cancer screen. Interview participants expanded on their experiences with healthcare in their local areas, sharing narratives of both positive and negative encounters. Positive clinical interactions were more common among participants who were receiving medication for opioid use disorder from their primary care provider or those who travel outside of their local area to receive care. Still, many participants reported stigmatizing experiences in the healthcare setting. When discussing a recent encounter in her local emergency department, Laura said, “. . . the staff treats you like shit and then they laugh at you. You can actually hear them . . . they were reluctant to treat me, they wouldn’t listen to me, there was only one nurse there that actually treated me like I was a human being. They just were rushin’ me out the door.”

Carol, a 62-year-old woman who uses opioids nonmedically echoed Laura’s sentiment, stating “To me, if you don’t like people, then you shouldn’t be working with healthcare, you know?...They [hospital staff] were all very rude and opinionated about the kind of medicine you’ve already been maybe taking for years.”

In this way, prior negative experiences in the clinical setting due to drug use status and the expectation of being treated poorly in the future created a barrier to engagement with healthcare that interrupted awareness of screening guidelines and receipt of screening tests.
Table 4. Association between healthcare experiences and personal and family cancer history with screening adherence.

|                      | Cervical |          |          | Breast |          |          | Colorectal |          |          | Lung |          |          |
|----------------------|----------|----------|----------|--------|----------|----------|------------|----------|----------|------|----------|----------|
|                      | Past Due | Current  | *p*      | Past Due| Current  | *p*      | Past Due   | Current  | *p*      | Past Due| Current  | *p*      |
| SHE-1: Have you ever avoided health care because of your drug use? (% yes) | 80.0     | 69.2     | 0.412    | 75.0   | 100      | 0.571    | 58.3       | 75.0     | 0.511    | 57.1   | N/A      | N/A      |
| SHE-2: Have you ever had a healthcare worker refuse to treat you or denied you access to medical treatment or care because of your drug use? (% yes) | 33.3     | 38.5     | 0.544    | 75.0   | 33.3     | 0.371    | 41.7       | 25.0     | 0.511    | 42.9   | N/A      | N/A      |
| SHE-3: Do you feel ‘accepted’ and ‘non-judged’ during office visits? (% “yes, and they know about the drug use” vs. “yes, but they don’t know about the drug use”, or “no, they treat me differently”) | 26.7     | 61.5     | 0.171    | 25.0   | 33.3     | 0.084    | 25.0       | 75.0     | 0.155    | 28.6   | N/A      | N/A      |
| SHE-4: Have you ever had bad experiences with primary care such that you considered not going anymore? (% yes) | 66.7     | 46.2     | 0.239    | 100    | 66.7     | 0.429    | 66.7       | 50.0     | 0.489    | 71.4   | N/A      | N/A      |
| Have you ever been told by a health care provider that you have a cancer? (% yes) | 20.0     | 15.4     | 0.572    | 25.0   | 0        | 0.571    | 8.3        | 25.0     | 0.450    | 14.3   | N/A      | N/A      |
| Has a parent, sibling, or child related to you by blood ever been diagnosed with cancer? (% yes) | 53.3     | 91.7     | 0.038 *  | 50.0   | 100      | 0.286    | 83.3       | 25.0     | 0.063    | 64.3   | N/A      | N/A      |

* The single response of “I don’t know/am unsure” was removed here.
4. Discussion

For this pilot study, conducted during the height of the COVID-19 pandemic, we were able to recruit 37 rural people who use drugs to complete telephone administered surveys, and 8 then were selected for follow up interviews. Due to age differences in gender-based screening guidelines, there were differences in age and smoking pack years between males and females. Further, the majority of males (55.5%) were married or cohabitating versus a minority of females (34.2%). The data indicate some healthy and risk reduction behaviors, such as a majority reporting past month exercise and only a minority reporting past month alcohol use. There may be differences in stigmatizing healthcare experiences, but the significance is difficult to ascertain due to the small sample size. Still, a larger proportion of females report such experiences.

Receipt of screening recommendations and tests varied considerably by type. The majority of females reported receiving recommendations for cervical and breast cancer screening, and a majority also reported ever-receipt. Only approximately half of males and females reported receipt of colorectal cancer screening recommendations, and less than half reported ever-receipt; and only one female and no males reported receipt of a lung cancer screening recommendation or test. While many reported ever-receipt of the various screens for which they were eligible, the majority (62.2%) were also past due for at least one screen (i.e., 23 individuals were past due for a total of 44 screens). In comparison, we observe that participant self-reported screening adherence for every screen is far less than that for Illinois, the United States, and rural areas in general (Table 2). Our data also indicated, but not to a statistically significant degree, that past stigmatizing experiences may be associated with screening nonadherence, and these indications from the survey data are supported by the interviews.

Interview data point to an important barrier to receipt of cancer screenings—transportation. Most participants report relying on friends or family for transportation to places they need to go. These arrangements are not always reliable, and many participants reported being "blown off", resulting in them missing their appointments. Additionally, public transit, while usually reliable, was reported as problematic due to waiting times and now COVID-19. The data also offer some possible insight into modes of healthcare delivery that may be more acceptable for PWUD. When asked about the feasibility and acceptability of receiving healthcare, including some cancer screening tests, at a mobile or off-clinic site, nearly all participants vocalized that they would feel more comfortable and better able to access healthcare if offered through this venue.

In toto, the survey and interview data support the idea that rural people who use drugs not only experience the rural circumstance of less frequent cancer screening, but the compounding influence their drug use may have on healthcare seeking and receipt. Past stigmatizing experiences increase reticence to seek care, lessening an already-lower likelihood of receiving appropriate screening recommendations. The data show, for example, that only 39% of females report having a primary care provider they see on a regular or routine basis, and 57% report having past bad experiences with primary care such that they considered not going anymore. In this light, data indicating the majority of females (and males) are past due for every screen for which they are eligible, and interview comments suggestive that care provided in other venues might be preferred, are consistent and point to areas of further work and development. As the opioid and other drug use (e.g., methamphetamine) epidemic continues to grow and evolve, developing better means to satisfactorily engage people who use drugs in healthcare, and exploring alternative means whereby care can be provided, becomes increasingly critical. The scale of those at compounding risk for missed/delayed screening is substantial, with estimates of past year use among those aged 12+ years of methamphetamine, heroin, and prescription pain killers (misuse) at 2.5 million, 90,000, and 9.3 million, respectively [55]. Further, there are some studies indicating that drug use may be associated with increased cancer risk [56–58]. As already shown, rural areas are disproportionately impacted by drug use, and so to avoid
increasing the existing rural disparities in cancer screening new means of engagement and utilization, specifically developed for the rural environment should be explored [26,27].

There are limitations to this work. The survey data are too few for more rigorous statistical analyses (e.g., insufficient variation in sexual orientation; drug of choice; frequency and methods of use). More extensive data would allow for exploration regarding how screening utilization might vary by important variables such as type(s) of drug use, age and previous experiences, and other stigmatizing characteristics; and how negative experiences/perceptions might be countered by intervention. From the interviews, the data are not sufficient to reach saturation, and findings are preliminary. Future interviews should explore these emergent themes more fully, particularly in relation to cancer screening priority, as preliminary findings indicate some indifference toward cancer screening adherence.

5. Conclusions

In conclusion, this work may be among the first to explicitly examine cancer screening experiences among rural people who use drugs. The drug use epidemic in the US is continuing to grow, often disproportionally impacting rural communities, and exacerbating existing disparities in healthcare utilization and cancer screening utilization. Our preliminary data indicates that rural people who use drugs may need specific consideration for interventions to increase cancer screening uptake, as the stigmatizing nature of their drug use adds additional barriers to seeking already-diminishing care in rural areas.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijerph19084555/s1, File S1: Survey instrument and interview guide.

Author Contributions: W.D.J. developed the project, oversaw data collection, performed statistical analysis and developed the manuscript. J.R. assisted with project development and contributed to manuscript development and revision. Y.M. assisted with project development and contributed to manuscript development and revision. M.L. assisted with project development and contributed to manuscript development and revision. R.B. led data collection and contributed to manuscript development and revision. G.L. assisted with data analysis and manuscript revision. B.V.H. led data collection and contributed to manuscript development and revision. All authors have read and agreed to the published version of the manuscript.

Funding: The research presented in this paper is that of the authors and does not reflect the official policy of the NIH. This work was partially supported by a grant from the NIH/NIDA (4UH3DA044829-03/04/05).

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board of University of Chicago (protocol code IRB17-1630; 20 March 2018). Informed consent was obtained from all subjects involved in the study.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The data presented in this study are available on request from the corresponding author. The data are not publicly available due to the sensitive nature of the data collected and other study aims exploring illicit drug use.

Conflicts of Interest: W.D.J., M.L., R.B. and B.V.H. were partially supported by a grant from the NIH/NIDA (4UH3DA044829-03/04/05) for this work. None of the authors report any other funding associated with this work. The study sponsor did not have any role in study design; collection, analysis, and interpretation of data; writing the report; and the decision to submit the report for publication.
References

1. US Census Bureau. Defining Rural at the U.S. Census Bureau. American Community Survey and Geography Brief. Available online: https://www.census.gov/library/stories/2017/08/rural-america.html (accessed on 23 September 2020).

2. Zahnd, W.E.; Rodriguez, C.; Jenkins, W.D. Rural-Urban Differences in Human Papillomavirus-associated Cancer Trends and Rates. J. Rural Health 2018, 35, 208–215. [CrossRef] [PubMed]

3. Zahnd, W.E.; James, A.S.; Jenkins, W.D.; Iadi, S.R.; Fogelman, A.J.; Steward, D.E.; Colditz, G.A.; Brand, L. Rural-Urban Differences in Cancer Incidence and Trends in the United States. Cancer Epidemiol. Biomark. Prev. 2018, 27, 1265–1274. [CrossRef] [PubMed]

4. Zahnd, W.E.; Fogelman, A.J.; Jenkins, W.D. Rural-Urban Disparities in Stage of Diagnosis Among Cancers with Preventive Opportunities. Am. J. Prev. Med. 2018, 54, 688–698. [CrossRef] [PubMed]

5. Henley, S.J.; Anderson, R.N.; Thomas, C.C.; Massetti, G.M.; Peaker, B.; Richardson, L.C. Invasive Cancer Incidence, 2004–2013, and Deaths, 2006–2015, in Nonmetropolitan and Metropolitan Counties—United States. MMWR Surveill. Summ. 2017, 66, 1–13. [CrossRef] [PubMed]

6. Cohen, S.A.; Cook, S.K.; Kelley, L.; Foutz, J.D.; Sando, T.A. A Closer Look at Rural-Urban Health Disparities: Associations Between Obesity and Rurality Vary by Geospatial and Sociodemographic Factors. J. Rural Heal. 2017, 33, 167–179. [CrossRef]

7. Warren, J.C.; Smalley, K.B.; Barefoot, K.N. Recent Alcohol, Tobacco, and Substance Use Variations between Rural and Urban Middle and High School Students. J. Child Adolesc. Subst. Abus. 2017, 26, 60–65. [CrossRef]

8. Dixon, M.A.; Chartier, K.G. Alcohol Use Patterns Among Urban and Rural Residents: Demographic and Social Influences. Alcohol Res. 2016, 38, 69–77.

9. Befort, C.A.; Nazir, N.; Engelman, K.; Choi, W. Fatalistic cancer beliefs and information sources among rural and urban adults in the USA. J. Cancer Educ. 2013, 28, 521–526. [CrossRef]

10. Hughes, A.G.; Watanabe-Galloway, S.; Schnell, P.; Soliman, A.S. Rural-Urban Differences in Colorectal Cancer Screening Barriers in Nebraska. J. Community Health 2015, 40, 1065–1074. [CrossRef]

11. Davis, T.C.; Rademaker, A.; Bailey, S.C.; Platt, D.; Esparza, J.; Wolf, M.S.; Arnold, C.L. Contrasts in rural and urban barriers to colorectal cancer screening. Am. J. Health Behav. 2013, 37, 289–298. [CrossRef]

12. Quinn, G.P.; Sanchez, J.A.; Sutton, S.K.; Vadaparampil, S.T.; Nguyen, G.; Green, B.L.; Kanetsky, P.A.; Schabath, M. Cancer and lesbian, gay, bisexual, transgender/transsexual, and queer/questioning (LGBTQ) populations. CA Cancer J. Clin. 2015, 65, 384–400. [CrossRef] [PubMed]

13. Lehavot, K.; Bloshnich, J.R.; Glass, J.E.; Williams, E.C. Alcohol use and receipt of alcohol screening and brief intervention in a representative sample of sexual minority and heterosexual adults receiving health care. Drug Alcohol Depend. 2017, 179, 240–246. [CrossRef] [PubMed]

14. Kerr, D.L.; Ding, K.; Chaya, J. Substance use of lesbian, gay, bisexual and heterosexual college students. Am. J. Health Behav. 2014, 38, 951–962. [CrossRef] [PubMed]

15. Dermody, S.S.; Marshal, M.P.; Cheong, J.; Burton, C.; Hughes, T.; Aranda, F.; Friedman, M.S. Longitudinal disparities of hazardous drinking between sexual minority and heterosexual individuals from adolescence to young adulthood. J. Youth Adolesc. 2014, 43, 30–39. [CrossRef] [PubMed]

16. Zull, H. Tobacco Product Use Among Lesbian, Gay, and Bisexual Adolescents. Pediatrics 2017, 139, e20163276. [CrossRef]

17. Gonzales, G.; Przedworski, J.; Henning-Smith, C. Comparison of Health and Health Risk Factors Between Lesbian, Gay, and Bisexual Adults and Heterosexual Adults in the United States: Results from the National Health Interview Survey. JAMA Intern. Med. 2016, 176, 1344–1351. [CrossRef] [PubMed]

18. American Society on Aging. Rural America Faces Shortage of Physicians to Care for Rapidly Aging Population. Available online: https://www.asaging.org/blog/rural-america-faces-shortage-physicians-care-rapidly-aging-population (accessed on 5 August 2020).

19. NPR; The Robert Wood Johnson Foundation; Harvard, T.H.; Chan School of Public Health. Life in Rural America—Part II. Available online: https://www.rwjf.org/en/library/research/2019/05/life-in-rural-america--part-ii.html (accessed on 5 August 2020).

20. The Chartis Group. The Rural Health Safety Net Under Pressure: Rural Hospital Vulnerability. Available online: https://www.chartis.com/forum/insight/the-rural-health-safety-net-under-pressure-rural-hospital-vulnerability/ (accessed on 5 August 2020).

21. Bennett, K.J.; Pumkam, C.; Bellinger, J.D.; Probst, J.C. Cancer screening delivery in persistent poverty rural counties. J. Prim. Care Community Health 2011, 2, 240–249. [CrossRef] [PubMed]

22. Davis, T.C.; Arnold, C.L.; Rademaker, A.; Bailey, S.C.; Platt, D.J.; Reynolds, C.; Esparza, J.; Liu, D.; Wolf, M.S. Differences in barriers to mammography between rural and urban women. J. Women’s Health 2012, 21, 748–755. [CrossRef]

23. National Institutes of Health. National Survey of Drug Use and Health. Available online: https://www.drugabuse.gov/drug-topics/trends-statistics/national-drug-early-warning-system-ndews/national-survey-drug-use-health (accessed on 13 September 2020).

24. Grant, B.F.; Saha, T.D.; Ruan, W.J.; Goldstein, R.; Chou, S.P.; Jung, J.; Zhang, H.; Smith, S.M.; Pickering, R.P.; Huang, B.; et al. Epidemiology of DSM-5 Drug Use Disorder: Results from the National Epidemiologic Survey on Alcohol and Related Conditions-III. JAMA Psychiatry 2016, 73, 39–47. [CrossRef]
25. Lansky, A.; Finlayson, T.; Johnson, C.; Holtzman, D.; Weinert, C.; Mitsch, A.; Gust, D.; Chen, R.; Mizuno, Y.; Crepaz, N. Estimating the number of persons who inject drugs in the United States by meta-analysis to calculate national rates of HIV and hepatitis C virus infections. *PLoS ONE* **2014**, *9*, e97596. [CrossRef]

26. Gray, M.E.; McQuade, E.T.R.; Scheld, W.M.; Dillingham, R.A. Rising rates of injection drug use associated infective endocarditis in Virginia with missed opportunities for addiction treatment referral: A retrospective cohort study. *BMC Infect. Dis.* **2018**, *18*, 1–9. [CrossRef] [PubMed]

27. Centers for Disease Control and Prevention. Rural America in Crisis: The Changing Opioid Overdose Epidemic. Available online: https://blogs.cdc.gov/publichealthmatters/2017/11/opioids/ (accessed on 27 March 2020).

28. Substance Abuse and Mental Health Services Administration (SAMHSA), Results from the 2018 National Survey on Drug Use and Health: Detailed Tables. Available online: https://www.samhsa.gov/data/sites/default/files/cbhsq-reports/NSDUHDetailedTabs2018R2/NSDUHDetailedTabsTOC2018.htm#toc (accessed on 13 September 2020).

29. Crapanzano, K.; Vath, R.J.; Fishier, D. Internalized stigma towards substance users through an educational intervention: Harder than it looks. *Acad. Psychiatry* **2014**, *38*, 420–425. [CrossRef] [PubMed]

30. Van Boekel, L.C.; Brouwers, E.P.; van Weeghel, J.; Garretsen, H.F. Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: Systematic review. *Drug Alcohol Depend.* **2013**, *131*, 23–35. [CrossRef] [PubMed]

31. Ahern, J.; Stuber, J.; Galea, S. Stigma, discrimination and the health of illicit drug users. *Drug Alcohol Depend.* **2007**, *88*, 188–196. [CrossRef] [PubMed]

32. Link, B.G.; Struening, E.L.; Rahav, M.; Phelan, J.C.; Nuttbrock, L. On stigma and its consequences: Evidence from a longitudinal study of men with dual diagnoses of mental illness and substance abuse. *J. Health Soc. Behav.* **1997**, *38*, 177–190. [CrossRef]

33. Kang, E.; Rapkin, B.D.; Remien, R.H.; Mellins, C.A.; Oh, A. Multiple dimensions of HIV stigma and psychological distress among Asians and Pacific Islanders living with HIV illness. *AIDS Behav.* **2005**, *9*, 145–154. [CrossRef]

34. Lee, R.S.; Kochman, A.; Sikkema, K.J. Internalized stigma among people living with HIV/AIDS. *AIDS Behav.* **2002**, *6*, 309–319. [CrossRef] [PubMed]

35. Vanabe, P.A.; Carey, M.P.; Blair, D.C.; Littlewood, R.A. Impact of HIV-related stigma on health behaviors and psychological adjustment among HIV-positive men and women. *AIDS Behav.* **2006**, *10*, 473–482. [CrossRef]

36. Stutterheim, S.E.; Pryor, J.B.; Bos, A.E.; Hoogendijk, J.; Murs, P.; Schalma, H.P. HIV-related stigma and psychological distress: The harmful effects of specific stigma manifestations in various social settings. *AIDS Behav.* **2009**, *23*, 2353–2357. [CrossRef]

37. Schmutte, T.; Flanagan, E.; Bedregal, L.; Riddaway, P.; Sells, D.; Styron, T.; Davidson, L. Self-efficacy and self-care: Missing ingredients in health and healthcare among adults with serious mental illnesses. *Psychiatr. Q.* **2009**, *80*, 1–8. [CrossRef]

38. Druss, B.G.; Rosenheck, R.A. Use of medical services by veterans with mental disorders. *J. Psychosom. Res.* **1997**, *38*, 451–458. [CrossRef]

39. Druss, B.G.; Rosenheck, R.A. Mental disorders and access to medical care in the United States. *Am. J. Psychiatry* **1998**, *155*, 1775–1777. [CrossRef] [PubMed]

40. Corrigan, P. How stigma interferes with mental health care. *Am. Psychol.* **2004**, *59*, 614–625. [CrossRef] [PubMed]

41. Corrigan, P.W.; Watson, A.C.; Barr, L. The self–stigma of mental illness: Implications for self–esteem and self–efficacy. *J. Soc. Clin. Psychol.* **2006**, *25*, 875–884. [CrossRef]

42. Bolinski, R.; Ellis, K.; E Zahnd, W.; Walters, S.; McCluckie, C.; Schneider, J.; Rodriguez, C.; Ezell, J.; Friedman, S.; Pho, M.; et al. Social norms associated with opioid misuse in rural communities: A systematic review. *Transl. Behav. Med.* **2019**, *9*, 1224–1232. [CrossRef]

43. Jenkins, W.D.; Bolinski, R.; Bressett, J.; van Ham, B.; Fletcher, S.; Walters, S.; Friedman, S.; Ezell, J.M.; Pho, M.; Schneider, J.; et al. COVID-19 During the Opioid Epidemic—Exacerbation of Stigma and Vulnerabilities. *J. Rural Health* **2020**, *37*, 172–174. [CrossRef]

44. US Preventive Services Task Force. Breast Cancer: Screening. Available online: https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening (accessed on 22 September 2020).

45. US Preventive Services Task Force. Cervical Cancer: Screening. Available online: https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/cervical-cancer-screening?ds=1&s=Cervical%20cancer (accessed on 22 September 2020).

46. US Preventive Services Task Force. Final Recommendation Statement: Screening for Colorectal Cancer. Available online: https://www.uspreventiveservicestaskforce.org/uspstf/announcements/final-recommendation-statement-screening-colorectal-cancer (accessed on 22 September 2020).

47. US Department of Health and Human Services. State Cancer Profiles. Available online: https://statecancerprofiles.cancer.gov/index.html (accessed on 15 January 2022).

48. US Preventive Services Task Force. Lung Cancer: Screening. Available online: https://www.uspreventiveservicestaskforce.org/uspstf/draft-recommendation/lung-cancer-screening-2020 (accessed on 22 September 2020).

49. Hall, I.J.; Tangka, F.K.; Sabatino, S.A.; Thompson, T.D.; Graubard, B.I.; Breen, N. Patterns and Trends in Cancer Screening in the United States. *Prev. Chronic Dis.* **2018**, *15*, E97. [CrossRef]

50. Locklar, L.R.B.; Do, D.P. Rural-urban differences in HPV testing for cervical cancer screening. *J. Rural Health* **2021**, *38*, 409–415. [CrossRef]
51. America’s Health Ranking. Colorectal Cancer Screening in Illinois. Available online: https://www.americashealthrankings.org/explore/annual/measure/colorectal_cancer_screening/population/colorectal_cancer_screening_less_HS/state/IL (accessed on 15 January 2022).
52. Shete, S.; Deng, Y.; Shannon, J.; Fasera, B.; Middleton, D.; Iachan, R.; Bernardo, B.; Balkrishnan, R.; Kim, S.J.; Huang, B.; et al. Differences in Breast and Colorectal Cancer Screening Adherence Among Women Residing in Urban and Rural Communities in the United States. JAMA Netw. Open 2021, 4, e2128000. [CrossRef]
53. American Lung Association. Lung Cancer Screening. Available online: https://www.lung.org/research/state-of-lung-cancer/states/illinois (accessed on 15 January 2022).
54. Carmichael, H.; Cowan, M.; McIntyre, R.; Velopulos, C. Disparities in colorectal cancer mortality for rural populations in the United States: Does screening matter? Am. J. Surg. 2020, 219, 988–992. [CrossRef]
55. Zgodic, A.; Zahnd, W.E.; Advani, S.; Eberth, J.M. Low-dose CT lung cancer screening uptake: A rural-urban comparison. J. Rural Health 2022, 38, 40–53. [CrossRef] [PubMed]
56. Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results from the 2020 National Survey on Drug Use and Health (HHS Publication No. PEP21–07–01–003, NSDUH Series H-56); Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration: Rockville, MD, USA, 2021. Available online: https://www.samhsa.gov/data/ (accessed on 18 March 2022).
57. Lacson, J.C.; Carroll, J.D.; Tuazon, E.; Castelao, E.J.; Bernstein, L.; Cortessis, V.K. Population-based case-control study of recreational drug use and testis cancer risk confirms an association between marijuana use and nonseminoma risk. Cancer 2012, 118, 5374–5383. [CrossRef] [PubMed]
58. Harlow, B.L.; Cramer, D.W.; Baron, J.A.; Titus-Ernstoff, L.; Greenberg, E.R. Psychotropic medication use and risk of epithelial ovarian cancer. Cancer Epidemiol. Biomark. Prev. 1998, 7, 697–702.